Redeye comments on Active Biotech's first quarter report. Patient enrolment has resumed in the myelofibrosis study in the US. The protocol amendment approval is expected shortly in Europe. There is an intensified focus on business development for laquinimod, which has the potential to drive the share.
LÄS MER
